
Supplements and Featured Publications
- Economic Impact of Irritable Bowel Syndrome: What Does the Future Hold?
- Volume 11
- Issue 1 Suppl
Participating Faculty
The American Journal of Managed Care
This supplement to contains information regarding the economic and medical impact of irritable bowel syndrome. This supplement has been reviewed by an expert in the field.
Faculty
Daniel Aguilar, MPH
Cerner Health Insights
Associate Director
Novartis Pharmaceuticals Corporation
Senior Clinical Analyst
Blue Bell, Pennsylvania
Judith Bentkover, PhD
Innovative Health Solutions
Senior Consultant
Brookline, Massachusetts
Stephen J. Boccuzzi, PhD
Aetna Health Information Solutions
Assistant Professor of Medicine
Bethesda, Maryland
Bonnie B. Dean, PhD
Cerner Health Insights
Senior Analyst
Blue Bell, Pennsylvania
Feride Frech, MPH
Health Economics and Outcomes Research
East Hanover, New Jersey
Ian M. Gralnek, MD, MSHS
David Geffen School of Medicine
VA Greater Los Angeles Healthcare System
Center for the Study of Digestive Healthcare Quality and Outcomes
Vice President
Detroit, Michigan
Samuel Joo, MS
Aetna Health Information Solutions
Director
Novartis Pharmaceuticals Corporation
Manager
Brookline, Massachusetts
Joshua J. Ofman, MD
Reimbursement and Payment Policy
Thousand Oaks, California
Dean G. Smith, PhD
Department of Health Management and Policy
School of Public Health
Assistant Professor of Medicine
VA Greater Los Angeles Healthcare System
University of California Los Angeles
Los Angeles, California
Judith J. Stephenson, SM
Aetna Health Information Solutions
President and Chief Executive Officer
Scottsdale, Arizona
Faculty Disclosure
The American Journal of Managed Care
It is the policy of to have all faculty who participate in programs sponsored by corporate organizations disclose any real or apparent conflicts of interest.
These participants have declared no financial affiliations with any corporate organizations:
- Daniel Aguilar, MPH
- Judith Bentkover, PhD
- Stephen J. Boccuzzi, PhD
- Joaquim Fernandes, BA
- Samuel Joo, MS
- Joshua J. Ofman, MD
- Brennan M. R. Spiegel, MD, MSHS
- Sean Sullivan, JD
These participants are employed by Novartis Pharmaceuticals:
- Victoria Barghout, MSPH
- Kristijan H. Kahler, SM
These participants have disclosed the following relationships with corporate organizations:
- Brooks Cash, MD, FACP Consultant To: Novartis Pharmaceuticals
Research Support From:
- AstraZeneca
- Janssen and Eisai
- Roche TAP
The American Journal of Managed Care,
Signed disclosures are on file at the offices of Jamesburg, New Jersey.
This program is supported by an educational grant from Novartis Pharmaceuticals.
The contents of this supplement may include information regarding the use of products that may be inconsistent with or outside the approved labeling for these products in the United States. Physicians should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.
Articles in this issue
over 20 years ago
Tegaserod Treatment for IBS: A Model of Indirect Costsover 20 years ago
Total Costs of IBS: Employer and Managed Care Perspectiveover 20 years ago
Budget Impact of Tegaserod on a Managed Care Organization FormularyNewsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.